320 related articles for article (PubMed ID: 23852185)
21. Gene therapy for hemophilia.
Ponder KP
Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
[TBL] [Abstract][Full Text] [Related]
22. Gene Therapy for Hemophilia.
Nienhuis AW; Nathwani AC; Davidoff AM
Mol Ther; 2017 May; 25(5):1163-1167. PubMed ID: 28411016
[TBL] [Abstract][Full Text] [Related]
23. AAV-mediated gene transfer for hemophilia.
High KA
Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
[TBL] [Abstract][Full Text] [Related]
24. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
Kim HS; Kim JC; Lee YK; Kim JS; Park YS
J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
[TBL] [Abstract][Full Text] [Related]
25. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
Herzog RW; High KA
Thromb Haemost; 1999 Aug; 82(2):540-6. PubMed ID: 10605748
[No Abstract] [Full Text] [Related]
26. Gene Therapy for Hemophilia.
Nathwani AC; Davidoff AM; Tuddenham EGD
Hematol Oncol Clin North Am; 2017 Oct; 31(5):853-868. PubMed ID: 28895852
[TBL] [Abstract][Full Text] [Related]
27. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
[TBL] [Abstract][Full Text] [Related]
28. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
Fabb SA; Dickson JG
Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
[TBL] [Abstract][Full Text] [Related]
30. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Ohmori T
Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
32. Advances and challenges for hemophilia gene therapy.
Batty P; Lillicrap D
Hum Mol Genet; 2019 Oct; 28(R1):R95-R101. PubMed ID: 31332444
[TBL] [Abstract][Full Text] [Related]
33. The gene therapy journey for hemophilia: are we there yet?
High KA
Hematology Am Soc Hematol Educ Program; 2012; 2012():375-81. PubMed ID: 23233607
[TBL] [Abstract][Full Text] [Related]
34. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
35. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
36. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
37. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
[TBL] [Abstract][Full Text] [Related]
38. Advances in Gene Therapy for Hemophilia.
Nathwani AC; Davidoff AM; Tuddenham EGD
Hum Gene Ther; 2017 Nov; 28(11):1004-1012. PubMed ID: 28835123
[TBL] [Abstract][Full Text] [Related]
39. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
Monahan PE
Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
[TBL] [Abstract][Full Text] [Related]
40. Gene therapy. Side effects sideline hemophilia trial.
Kaiser J
Science; 2004 Jun; 304(5676):1423-5. PubMed ID: 15178771
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
